Abstract 214P
Background
Translocation renal cell carcinoma (TRCC) represents 1% to 5% of all cases of renal cell carcinoma (RCC), with the highest frequency among children and young adults. Management of these tumors is ill defined. This is a retrospective analysis of treatment outcome in adult patient 18 years or above treated at our hospital between Janaury 2013 to November 2019.
Methods
Clinical and pathological data of 26 patients from a single institution diagnosed with TRCC between January 2013 and November 2019 were retrospectively reviewed. We analyzed our data of patients treated with Surgery only or who progressed after surgery and treated with systemic therapy or who upfront due to unresectable or metastatic disease treated with systemic therapy with respect to Event free survival and overall survival.
Results
Between Jan 2013 to Nov 2018, 26 adult patients were treated at our centre. Out of 26 patients 25 had radical surgery after evaluation and 1 had metastatic disease who was started on systemic therapy. Out 25 patient who were treated with radical surgery, 16 patients progressed and they were started on systemic therapy. Median EFS and median OS among overall population was 22 month and 30 month respectively. Among 16 patient who were treated with systemic therapy, median EFS to first line therapy was 8 month and to second line therapy was 2.5 month. Median OS was 17 month.
Conclusions
TFE RCC is rarely seen but carries significant risk of disease progression with potential response to targeted therapy of short duration.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ajaykumar Singh.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
393P - Clinical characteristics and prognosis of patients with pulmonary mucoepidermoid carcinoma: A SEER-based analysis
Presenter: Lingxiao Qiu
Session: e-Poster Display Session
394P - Apatinib plus etoposide capsules as third-line or further-line treatment for extensive stage small cell lung cancer patients: A multicenter, single arm, phase II clinical trial
Presenter: Zhen He
Session: e-Poster Display Session
395P - Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
396P - Efficacy and safety of S-1 in elderly patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: A subgroup analysis of the EAST-LC
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
397P - A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients
Presenter: Ching-Liang Ho
Session: e-Poster Display Session
398P - Real-world mechanism of crizotinib-resistance in MET exon 14 skipping mutations non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Dong Wang
Session: e-Poster Display Session
399P - Real-world insights into patients (pts) with advanced NSCLC and MET alterations
Presenter: Marisa Bittoni
Session: e-Poster Display Session
400P - Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm+) NSCLC: Final analysis of Asian patients in the GioTag study
Presenter: Maximilian J. Hochmair
Session: e-Poster Display Session
401P - A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
Presenter: Satoshi Igawa
Session: e-Poster Display Session
402P - Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
Presenter: Zhehai Wang
Session: e-Poster Display Session